Europe — EMA

Palonosetron Kalceks

Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5‑HT3 receptor antagonist presented as a 0.075 mg/5 ml solution for intravenous use.

Palonosetron

Request sourcing

Pack/s

What is Palonosetron?

Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5‑HT3 receptor antagonist presented as a 0.075 mg/5 ml solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients. GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

What is Palonosetron used for?

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the prevention of nausea and vomiting in several clinical contexts.

- Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting protection against acute and delayed CINV. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: Helps ... (the ... ) ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →